ADGRL3 and cancer: Analogously, we can now assess the location of known pathological mutations: Avila-Zozaya et al. have investigated cancer-related mutations in ADGRL3, with impacts on G13-signaling for K561NH1.51, D798HS9.47, S810Ls9s10 and E811Qs9s10, where the latter two residues correspond to the interaction region of the GAIN domain with the seven-transmembrane domain19,56.